We are excited to announce that GCP ClinPlus has successfully completed the First Patient First Visit (FPFV) for Wingor Biotechnology’s Phase II clinical trial evaluating human umbilical cord mesenchymal stem cell (hUC-MSC) injections for acute ischemic stroke (AIS).Stroke is the leading health threat in China, with over 28 million patients and 3.3 million new cases each year. This important study is led by Beijing Tiantan Hospital, Capital Medical University (PI: Prof. Yongjun Wang), in collaboration with Shenzhen Second People’s Hospital, Yan’an University Xianyang Hospital, and other national advanced stroke centers.The trial is a randomized, blinded, placebo-controlled Phase II study, marking a major step forward in innovative stem cell therapies for AIS.At GCP ClinPlus, we are proud to be the leading Cell & Gene Therapy CRO in China, with 80+ CGT studies across multiple indications.To learn more about conducting CGT trials in China, contact us at global@gcp-clinplus.com